A Phase 1 interventional study of Comparator: Estrace 0.5 mg and Comparator: Estrace 2 mg in Postmenopausal Symptoms, sponsored by Merck Sharp & Dohme LLC. Completed. Open to female participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-01-22.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to examine the effect of two different dose levels of estrogen or placebo in healthy postmenopausal women by measuring the changes in hormone levels and examining the changes in the uterine lining (endometrium).
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Estrace 2.0 mg tablet
Drug: Comparator: Estrace 2 mg
Estrace 0.5 mg tablet
Drug: Comparator: Estrace 0.5 mg
Placebo
Drug: Comparator: Placebo
0.5 mg tablet taken once daily for 28 days
Also known as: Estrace
2 mg tablets taken once daily for 28 days.
Also known as: Estrace
Placebo 0 mg capsule taken once daily for 28 days
Immunohistochemistry (IHC) Proliferative Effects Measurement
Ratio of the total number of positively stained cell nuclei to the total number of cell nuclei. Proliferating endometrial cells express the Ki-67 antigen. The ratio was converted to a percent proliferating cells by taking the number of Ki-67 positive stained nuclei in a given field and dividing by the total number of nuclei in that field and multiplying by 100. At least 5 high power fields were scored in this manner and an aggregate percent Ki-67 positive cells was reported. Square root transformation was taken to make it approximately normally distributed for an ANOVA model to apply.
Time frame: 4 weeks
Mean Gene Expression Intensity After 4 Weeks of Either 0.5 or 2 mg Estrace Compared to Placebo.
Time frame: 4 weeks
Patients were recruited through advertisement and review of patient databases at Comprehensive Phase I, USA, between December 2008 and April 2009.
| Milestone | 17β-estradiol 2.0 Milligrams | 17β-estradiol 0.5 Milligrams | Placebo |
|---|---|---|---|
| Started | 9 | 11 | 9 |
| Completed | 9 | 11 | 9 |
| Not completed | 0 | 0 | 0 |
Ratio of the total number of positively stained cell nuclei to the total number of cell nuclei. Proliferating endometrial cells express the Ki-67 antigen. The ratio was converted to a percent proliferating cells by taking the number of Ki-67 positive stained nuclei in a given field and dividing by the total number of nuclei in that field and multiplying by 100. At least 5 high power fields were scored in this manner and an aggregate percent Ki-67 positive cells was reported. Square root transformation was taken to make it approximately normally distributed for an ANOVA model to apply.
| Square root of % positive stained cells | 17β-estradiol 2.0 Milligrams | 17β-estradiol 0.5 Milligrams | Placebo |
|---|---|---|---|
| Immunohistochemistry (IHC) Proliferative Effects Measurement | 0.73 (0.61 to 0.86) | 0.43 (0.32 to 0.54) | 0.25 (0.12 to 0.37) |
Results for this outcome have not been posted.
Collected over Reported AE data were collected during the period of the study from date of informed consent to the 14 day follow up period following completion of treatment.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 17β-estradiol 2.0 Milligrams | — | 0/9 (0%) | 7/9 (77.8%) |
| 17β-estradiol 0.5 Milligrams | — | 0/11 (0%) | 6/11 (54.5%) |
| Placebo | — | 0/9 (0%) | 6/9 (66.7%) |
| Event | 17β-estradiol 2.0 Milligrams | 17β-estradiol 0.5 Milligrams | Placebo |
|---|---|---|---|
| Vaginal HaemorrhageReproductive system and breast disorders | 4/9 | 1/11 | 0/9 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/9 | 0/11 | 3/9 |
| Abdominal DiscomfortGastrointestinal disorders | 2/9 | 0/11 | 0/9 |
| Abdominal PainGastrointestinal disorders | 2/9 | 2/11 | 2/9 |
| Blood Pressure IncreasedInvestigations | 0/9 | 0/11 | 2/9 |
| HeadacheNervous system disorders | 2/9 | 1/11 | 1/9 |
| Vulvovaginal PruritusReproductive system and breast disorders | 2/9 | 0/11 | 0/9 |
| Back PainMusculoskeletal and connective tissue disorders | 0/9 | 2/11 | 0/9 |
| DizzinessNervous system disorders | 1/9 | 2/11 | 1/9 |
| Vision BlurredEye disorders | 1/9 | 0/11 | 0/9 |
| Age, Continuous(years) | 17β-estradiol 2.0 Milligrams | 17β-estradiol 0.5 Milligrams | Placebo | Total |
|---|---|---|---|---|
| Mean | 54.11 ± 3.76 | 53.91 ± 5.65 | 55.33 ± 3.04 | 54.41 ± 4.30 |
| Sex: Female, Male(Participants) | 17β-estradiol 2.0 Milligrams | 17β-estradiol 0.5 Milligrams | Placebo | Total |
|---|---|---|---|---|
| Female | 9 | 11 | 9 | 29 |
| Male | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(participants) | 17β-estradiol 2.0 Milligrams | 17β-estradiol 0.5 Milligrams | Placebo | Total |
|---|---|---|---|---|
| Black | 1 | 0 | 0 | 1 |
| White | 8 | 11 | 9 | 28 |
| Body Mass Index (BMI)(kg/m^2) | 17β-estradiol 2.0 Milligrams | 17β-estradiol 0.5 Milligrams | Placebo | Total |
|---|---|---|---|---|
| Mean | 27.87 ± 3.95 | 28.69 ± 2.74 | 27.43 ± 1.98 | 28.05 ± 2.92 |
No study locations are listed for this record.
The record gives a start of Dec 2008, a primary completion of May 2009 and a completion of May 2009. It does not say whether these dates are actual or estimated.
Results were first posted in May 2010, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Estradiol